06 Jan Aridis Pharmaceuticals to Present at Biotech Showcase™ 2016
SAN JOSE, Calif. – January 6, 2016 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the Company will present at the Biotech Showcase™ 2016, taking place in San Francisco, CA, on January 11–13, 2016.
Vu Truong, Ph.D., Founder and Chief Executive Officer of Aridis Pharmaceuticals, will provide an overview of the Company’s business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Meetings with management may also be scheduled outside of Biotech Showcase by contacting Aridis’ investor relations.
Event: Biotech Showcase™ 2016
Date: Wednesday, January 13, 2016
Time: 10:45 am (Pacific Time)
Location: Parc 55 San Francisco
About Aridis Pharmaceuticals, Inc.
Aridis is a privately held biopharmaceutical company applying proprietary monoclonal antibody discovery technology MabIgX® to produce novel infectious disease focused therapies. Aridis’ product pipeline includes AR-101 (Aerumab®) anti-Pseudomonas aeruginosa LPS human monoclonal antibody; AR-301 (Salvecin®) anti-Staphylococcus aureus human monoclonal antibody to treat acute pneumonia; Aerucin®, a broadly reactive anti-Pseudomonas aeruginosa human monoclonal antibody initially being developed to treat acute pneumonia; Panaecin®, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; AR- 401 anti-Acinetobacter baumannii human monoclonal antibody; and AR-201 anti-RSV human monoclonal antibody.
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of Aerumab® (AR-101), Salvecin® (AR-301), Aerucin®, Panaecin®, AR-401, AR-201, Aridis’ proprietary formulation and delivery technologies, about Aridis’ strategy, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Aridis’ expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Aridis’ research and clinical studies and its ability to obtain additional financing. These forward-looking statements represent Aridis’ judgment as of the date of this release. Aridis disclaims any intent or obligation to update these forward-looking statements.
Tirth Patel (investors)
Andrew Mielach (media)